Alf Bernhardt

As physician with over 25 years of experience in oncology, haematology, and global medical affairs, I have a strong background in clinical research, medical affairs, and product launch in global and regional markets. My mission is to advance the science and practice of IO treatments and CellTherapies to ensure the best outcomes for patients. I have lead and supported the development and launch of several novel therapeutics and biomarkers for lymphoma, breast cancer, and other oncology indications. I have also contributed to multiple publications, patents, and certifications in the field of oncology and hematology. I am passionate about improving patients’ lives and delivering excellence in medical affairs and translational science.

Business Partners

Health in Focus

25+ years in oncology and haematology medical affairs — from bench to global launch.

I have built Medical Affairs organisations from zero, led landmark EMA and FDA approvals, and shaped the scientific strategy behind some of the most successful oncology launches in Europe and the US.

I work with biotech and pharma companies that need senior medical leadership — without the overhead.


25+

years in oncology &
haematology MA

18

people across 7 countries,
built in 12 months

18

peer-reviewed
publications

65+

Tier-1 KOL
relationships (Europe)

Medical Affairs Strategy

Building and structuring Medical Affairs functions — from team design and KOL strategy to publication planning and evidence generation.

Launch Excellence

Guiding clinical and commercial launch strategy in oncology and haematology — from regulatory filing through market access and early adoption.

Scientific Communications

Medical writing, publication strategy, and scientific review — turning complex data into clear, compliant, impactful content.

I integrate AI tools into Medical Affairs workflows — from literature monitoring and medical information to
field documentation and evidence synthesis.

Need expert support?

Are you facing medical, regulatory, or strategic challenges in healthcare? I support you with deep expertise, clear structure, and practical solutions.

Researches

Communicating knowledge clearly and applying it in practice – this is the goal of my research. I present complex medical and regulatory topics in a clear and structured way so they can be directly applied in everyday professional practice.

Recommandations:

“ Alf demonstrated outstanding leadership as the former Head of Pipeline and Cell Therapy in Global Medical Affairs at Takeda Oncology. He consistently demonstrated exceptional expertise and strategic vision in navigating the complexities of the oncology field. His ability to foster collaboration and inspire teams towards shared goals resulted in increased productivity and impactful outcomes. Alf excelled in communication, ensuring stakeholders were well-informed and engaged, while always prioritizing patient-centricity and integrity. I had the pleasure of witnessing Alf’s dedication and impact firsthand, and I am confident in endorsing him for any future opportunities he pursues. His contributions to the field of oncology were truly commendable, and I was grateful for the opportunity to work alongside such a talented professional.Alf demonstrated outstanding leadership as the former Head of Pipeline and Cell Therapy in Global Medical Affairs at Takeda Oncology. He consistently demonstrated exceptional expertise and strategic vision in navigating the complexities of the oncology field. His ability to foster collaboration and inspire teams towards shared goals resulted in increased productivity and impactful outcomes. Alf excelled in communication, ensuring stakeholders were well-informed and engaged, while always prioritizing patient-centricity and integrity. I had the pleasure of witnessing Alf’s dedication and impact firsthand, and I am confident in endorsing him for any future opportunities he pursues. His contributions to the field of oncology were truly commendable, and I was grateful for the opportunity to work alongside such a talented professional.”

Rachelle Mudrinich, MBA, CDMP, PCM
Marketing Director


Letter of Recommandation by Pulsus

I highly recommend Dr. Alf Bernhardt for any position that requires a seasoned and highly skilled Medical Hematologist and Oncologist with extensive experience in Global Medical Affairs and Development. I have had the pleasure of working closely with Alf Bernhardt during his tenure at Takeda Pharmaceuticals, where he served as the Global Head of Pipeline and Cell Therapy in the Global Medical Affairs Oncology department.

Alf Bernhardt is a board-certified Medical Hematologist and Oncologist with over 25 years of professional experience in the Biotechnology and Pharmaceutical Industry. His expertise spans across research and development, as well as local, regional, and global medical affairs leadership. With 10 years of hands-on experience as a medical doctor and consultant in oncology, hematology, and palliative care, he has consistently demonstrated exceptional clinical acumen and patient care.

In his role at Takeda Pharmaceutical Company Limited, Alf Bernhardt led and managed the global cross-functional oncology pipeline team, driving cross-portfolio asset strategies in early pipeline focusing on immuno-oncology, colorectal cancer, and lung cancer. His strategic decision-making and collaborative approach resulted in the successful revaluation of all pipeline assets from a clinical perspective and the establishment of the Medical Science Liaison (MSL) role in early trial management.

Previously, as the Head of Medical Affairs Europe at Seattle Genetics, he built and managed the Medical Affairs Department, overseeing governance and operations. He was instrumental in hiring and onboarding key personnel, including Medical Directors and MSLs, and played a pivotal role in the successful introduction of Tukysa as the treatment of choice for HER2+ breast cancer patients with CNS metastasis in Europe.

He is known for his keen mindset for agile and lean organizations, strong planning and organizational skills, and ability to develop and maintain strong collaborative relationships with key stakeholders. His customer-focused, outside-in thinking mindset, coupled with his analytical and strategic decision-making abilities, make him an invaluable asset to any organization. Dr. Alf Bernhardt is an active member of prestigious organizations such as DGHO, ASCO, and ASH, which further underscores his commitment to staying at the forefront of medical advancements and best practices.
In conclusion, I wholeheartedly recommend him for any role that requires a highly motivated, strategic, and collaborative medical professional. His extensive experience, leadership skills, and dedication to excellence make him an outstanding candidate for any organization. Please feel free to contact me at msdlima@pulsuspharma.com if you require any further information.

My Story

After years of shaping medical and science strategy at Roche, SeaGen and Takeda, I decided it’s time to found my own medical consulting company. My goal is to combine my clinical expertise in oncology and hematology with extensive global medical affairs, early launch, and market access experience across Europe and the US. If you’re looking for sharp insights, pragmatic solutions, and someone who knows the difference between a molecule and a miracle — I am your person

Dr. med. (Heinrich Heine University Düsseldorf) · Facharzt Hämatologie & Internistische Onkologie · Facharzt Innere Medizin
Swiss MEBEKO recognitions: Arzt · Hämatologie · Innere Medizin 
18 peer-reviewed publications · H-index 12 · Blood · JCO · Lancet Oncology · 40+ congress presentations

persons left hand with white background
person in black long sleeve shirt holding persons hand

The NemetzGroup

The Nemetz Group is a forward-thinking organization that delivers innovative, high-quality solutions to help clients achieve sustainable growth and long-term success.

Pulsus Pharma

Pulsus Pharma is a specialized consultancy that supports pharmaceutical companies with expert solutions in medical affairs, clinical research, and regulatory strategy to drive successful product development.